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Abstract
Friedreich’s Ataxia (FA) is an inherited neurodegenerative disorder resulting from
decreased expression of the mitochondrial protein frataxin, for which there is no approved
therapy. High throughput screening of clinically used drugs identified Dimethyl fumarate
(DMF) as protective in FA patient cells. Here we demonstrate that DMF significantly
increases frataxin gene (FXN) expression in FA cell model, FA mouse model and in DMF
treated humans. DMF also rescues mitochondrial biogenesis deficiency in FA-patient
derived cell model. We further examined the mechanism of DMF’s frataxin induction in FA
patient cells. It has been shown that transcription-inhibitory R-loops form at GAA expansion
mutations, thus decreasing FXN expression. In FA patient cells, we demonstrate that DMF
significantly increases transcription initiation. As a potential consequence, we observe sig-
nificant reduction in both R-loop formation and transcriptional pausing thereby significantly
increasing FXN expression. Lastly, DMF dosed Multiple Sclerosis (MS) patients showed
significant increase in FXN expression by ~85%. Since inherited deficiency in FXN is the pri-
mary cause of FA, and DMF is demonstrated to increase FXN expression in humans, DMF
could be considered for Friedreich’s therapy.
Introduction
Friedreich’s ataxia (FA) is caused by inheritance of GAA tri-nucleotide expansions and
reduced expression the mitochondrial protein frataxin. FA is an ultimately lethal neurodegen-
erative disease for which there is currently no approved therapy [1]. All pathophysiological
consequences, severity and age of onset of FA are directly related to the extent of frataxin defi-
ciency, greater the frataxin deficiency, worse the outcome [2–5]. Common symptoms
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associated with this disease include loss of muscle coordination, cardiomyopathy, hearing
defect and diabetes [6,7].
How deficiency of the mitochondrial protein frataxin triggers the FA pathomechanism is
still unclear, however the best evidence for frataxin’s physiological role is that it supports mito-
chondrial iron-sulfur cluster synthesis [8,9]. Recently we demonstrated that frataxin deficiency
in FA patient cells, FA mice, and FA human patients causes a mitochondrial biogenesis defect
[10], so it is possible that a primary defect in iron-sulfur clusters (which are essential for several
mitochondrial enzyme complexes) causes the mitochondrial biogenesis defect that ultimately
triggers the disease.
To identify therapeutic strategies we screened 1,600 drugs of known safety profiles that are
currently being used for other indications in humans [11]. Dimethyl fumarate (DMF) pro-
vided dose-dependent protection in cell-based screening. Chemically, DMF is methyl ester of
fumaric acid and is currently used to treat Multiple Sclerosis (MS) and Psoriasis [12]. Here, we
aim to analyze effect of DMF on Frataxin gene (FXN) expression in patient derived lympho-
blast cell model, mice model YG8 and in blood lymphocytes from humans dosed with DMF.
We demonstrate that DMF dose-dependently increases FXN expression both in FA patient
derived lymphoblast cells and in mouse in vivo. At the molecular level, inherited GAA repeats
are thought to repress FXN expression through the formation of thermodynamically stable R-
loop structure composed of an RNA-DNA hybrid and a displaced DNA single strand [13,14].
Presence of R-loop at expanded GAA site can result in stalling of RNA polymerase and prema-
ture transcription termination [15–17]. Mechanistically, we confirm that there are increased
R-loops at the GAA repeat regions in the FXN gene of patient derived lymphoblastoid cell line.
We further demonstrate that DMF significantly increases FXN expression in FA cells by
increasing transcription initiation which potentially decreases R-loop enrichment and further
reduces transcriptional stalling at GAA pause sites as demonstrated here. Because deficiency of
mitochondrial frataxin is the primary cause of FA, and DMF significantly increases FXN
expression in various models, we suggest that DMF could be considered as a potential therapy
for FA.
Results
DMF increases FXN expression in vitro and in vivo in FA cells and mice
models
To study the effect of DMF on FXN expression we treated patient-derived FA lymphoblast
cells GM14518, GM15850, GM16214, GM16216 and GM16220 that has different number of
GAA repeats (S1 Table) with 1, 3, 10, 30 and 100 μM DMF for 24 hr. FXN mRNA expression
was measured by qRT-PCR. We observed dose dependent increase in FXN mRNA expression
with significant increase at 10 μM and 30 μM DMF concentration by 25% and 93% respec-
tively, compared to their respective vehicle treated control (Fig 1A). The 100 μM dose was
toxic and triggered significant cell death and very low RNA yields. We also confirmed increase
in FXN expression at protein level with DMF treatment in lymphoblast cells (S1 Fig). Overall,
DMF significantly increased FXN expression in various patient derived lymphoblast cell
models.
To further determine if in vitro effects of DMF on FXN expression were translated in vivo
in FA YG8 mice model, mice (n = 4) were intra-peritoneally (IP) dosed with DMF at 0, 3, 5
and 10mg/kg concentration for 7 days. Cerebellum, which is a primary tissue affected in FA
was collected and frataxin protein level was measured by western blot. Consistently, we
observed significant dose-dependent increase in frataxin level by 23% and 52% respectively in
cerebellum of animal dosed with 5 and 10 mg/kg DMF compared to vehicle treated control
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animals (Fig 1B). Few representative images of frataxin western-blot from DMF treated YG8
mice model cerebellum is shown in (S2A & S2C Fig). Increase in frataxin was also observed in
spleen of DMF treated YG8 mice model (S2B Fig) and cerebellum of DMF treated KIKO mice
model (S2D Fig). Overall, DMF increases frataxin protein in the cerebellar tissue of various FA
mice models, which is the target tissue affected in FA.
DMF increases FXN expression in vivo in MS patients
12 controls and 27 MS patients were recruited from Multiple Sclerosis Center of the Federico
II University of Naples. Of these 27 MS patients, 14 were treated with DMF and 13 with Fingo-
limod (FTY). Blood was collected before and after 3 months of treatment and PBMCs were
isolated to determine FXN mRNA expression.
Baseline levels of FXN mRNA were similar between controls and MS. We observed signifi-
cant 85.1% increase in FXN expression in 3 months DMF treated MS patients. However, FXN
expression was not much affected in FTY treated patient patients (Fig 2). Overall, consistent
with cell and mice model, we observed a significant increase in FXN mRNA expression in
peripheral blood lymphocytes of DMF treated MS patient.
DMF induces transcription initiation and reduces transcriptional ’pausing’
in mutant FXN gene
The expanded GAA repeats that results in decreased FXN expression appear to do so by multi-
ple mechanisms. In particular, GAA repeats can cause RNA polymerase ’pausing’, which may
be the result of co-transcriptional R-loop structures [18,19]. We studied the consequences of
DMF dosing on FXN pre-mRNA transcription by qRT-PCR in patient derived lymphoblast
cell line GM-14518 with ~900 GAA repeats by using primers (S2 Table) that are designed to
follow RNA synthesis along the of FXN pre-mRNA (Fig 3). FXN pre-mRNA transcription
Fig 1. DMF dose dependently increases FXN expression in vitro in various patient derived lymphoblast cell models and in vivo in
YG8 mice model of FA. (A) Lymphoblast cells (GM14518, GM15850, GM16214, GM16216 and GM16220) were treated with 0.01%
DMSO vehicle, 1,3,10 or 30 μM DMF for 24hr. RNA was extracted and FXN expression was measured by qRT-PCR as FXN normalized
to Actin. Vehicle, n = 50; 1μM, n = 3; 3μM, n = 20; 10μM, n = 24; 30μM, n = 42. (B) Mice were IP dosed with 3,5 and 10 mg/kg DMF for
7 day. Protein was extracted from Cerebellar tissue and measured using Western Blot analysis as Frataxin normalized to Tubulin or
Actin. (n = 4; each group). Bars represent averages ± standard deviations (p<0.05�, p<0.01��, p<0.001���).
https://doi.org/10.1371/journal.pone.0217776.g001
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profile of patient cell line at different loci was compared to healthy individual derived lympho-
blast cell line GM-13068.
Consistent with a prior study [20], we observed 50% decrease in RNA transcript level in
patient cells, just downstream of the GAA repeats, consistent with the idea that GAA repeats
cause a ’stalling’ of RNA polymerase in this region, resulting in decreased FXN expression. We
observed additional transcriptional reduction along the transcript such that RNA levels were
60% lower than controls near Intron2-Exon3 and further reduced by 85% near exon 5, which
is representative of mature FXN transcript (Fig 3).
Interestingly, when we treated the same GM14518 patient cells with 30 μM DMF treatment
for 24 hour, we measured a 48% increase in transcript levels at the 5’UTR (Fig 3). In addition,
transcript level was significantly higher at all the loci downstream of GAA pause site, increas-
ing the level of mature transcript by ~146% compared to untreated patient cells, as measured
by Ex3-Ex4 primers and Ex5 primers. Thus, DMF appears to increases FXN expression by two
mechanisms: increased transcriptional initiation (Fig 3, UTR) and reversal of pausing (Fig 3,
Down-GAA to Ex5).
Fig 2. DMF increases FXN expression in peripheral blood mononuclear cells (PBMC’s) when dosed at 480mg/day in vivo in
humans. 27 MS patients were recruited and 14 were treated with DMF and 13 with FTY for 3 months. Blood was drawn post
treatment, PBMCs were isolated and FXN mRNA expression was measured pre and post treatment by qRT-PCR. Baseline values of
FXN/mRNA expression were set at 1 and 3 months values are shown relative to baseline values. CNTRL = Controls (n = 12);
DMF = Dimethylfumarate (n = 14); FTY = Fingolimod (n = 13);. Bars represent median ± error standard mean (p<0.05�).
https://doi.org/10.1371/journal.pone.0217776.g002
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DMF reduces R-loop concentrations at mutant FXN pause sites
One of the mechanism proposed for RNA polymerase transcriptional pausing in mutant FXN
is through the formation of R-loops structure [20]. R-loops formed over GAA repeats are
thought to silence FXN expression through the recruitment of repressive histone marks and
impairment of transcription caused by chromatin condensation. We tested whether DMF has
any effect on R-loop formation using DNA-RNA hybrid immuno-precipitation (DRIP) to
selectively enrich DNA-RNA hybrid containing R-loops in healthy lymphoblast cells GM-
13068, patient derived lymphoblast cells GM-14518, and in patient cells treated with 30 μM
DMF for 24 hr. DRIP was followed by qRT-PCR to detect R-loop enrichment at desired loca-
tions along the FXN gene. We observed a trend of increased R-loop enrichment at all loci near
GAA repeats in FA patient cells, with significant enrichment at Up GAA and down GAA loci
of FXN gene by 5 fold and 3.6 fold respectively (Fig 4) compared to healthy cells. Positive con-
trol gene loci, FBLX17 and TFPT showed higher R-loop enrichments both in healthy cells and
patient cells as expected. DMF treated patient cells showed an overall trend of decrease in R-
loop enrichment compared to untreated patient cells with significant decrease at UTR-Ex1
and UP GAA loci by 3.6 and 3.4 fold respectively. Interestingly, R-loop enrichment at TFPT
and FBLX17 were not affected by DMF treatment. As a negative control for this experiment,
Fig 3. DMF induces both increased transcription initiation and procession at GAA repeat pause site of FXN. FXN pre-mRNA
transcription was traced my qRT-PCR in healthy lymphoblast (GM-13068), patient derived lymphoblast (GM-14518) and in patient
lymphoblast cells (GM14518) treated with 30uM DMF for 24 hr. Bars represent averages ± standard deviations (n = 3, each group). Bars
represent averages ± standard deviations (p<0.05�, p<0.01��, p<0.001���).
https://doi.org/10.1371/journal.pone.0217776.g003
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DNA from patient derived lymphoblast cells was treated with RNase-H before DRIP. RNase-
H treatment decreased R-loop enrichment in patient cells at loci near GAA repeats in FXN
gene as well as decreased R-loop enrichment at positive control genes (S3 Fig).
Overall, DMF treatment reduced R-loop loads specifically around the GAA repeat region of
FXN, suggesting that the increased transcription observed in DMF treated patient cells might
be linked to the reduction of R-loop induced pausing.
DMF increases mitochondrial biogenesis in patient derived fibroblast cells
We recently demonstrated a mitochondrial biogenesis defect in FA patient cells, FA mice, and
FA patient blood lymphocyte tissue [10]. We also showed that the mitochondrial biogenesis
defect was dependent on FXN concentration through siRNA knockdown and over-expression
experiments. Furthermore, we showed that the mitochondrial biogenesis defect in FA patient
blood was directly and significantly correlated with their blood FXN expression (Jasoliya et al.,
2017). Given the highly energetic nature of neurons, this FXN-dependent mitochondrial
Fig 4. DMF reduces R-loop enrichment at GAA repeat pause site of FXN gene. R-loops were enriched using antibody specific for
RNA-DNA hybrid and fold enrichment measured relative to input DNA by qPCR in healthy lymphoblast (GM-13068), patient derived
lymphoblast (GM14518) and in patient lymphoblast cells (GM-14518) treated with 30uM DMF for 24 hr. Bars represent averages ± standard
deviations (n = 6, each group, p<0.05�, p<0.01��, p<0.001���).
https://doi.org/10.1371/journal.pone.0217776.g004
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biogenesis defect could be a significant contributor to the neurological patho-mechanism of
Friedreich’s ataxia. We treated FA fibroblasts GM-4078 with DMF for 48 hr. Total DNA was
extracted and FXN expression, and mitochondrial copy number per cell was measured as
mtDNA/nDNA ratio. Dose-dependent significant increases in mitochondrial copy number
and FXN expression were observed. Mitochondrial copy number was significantly increased at
10 μM and 30 μM concentration by 20% and 76% respectively compared to vehicle treated
control in 48hr DMF treated fibroblast cells (Fig 5B). Overall, DMF significantly increased
mitochondrial copy number in FA patient derived primary cells. We recently demonstrated
that DMF also increases mitochondrial biogenesis and gene expression in normal human
fibroblasts, control mice, and in humans with Multiple Sclerosis (Hayashi Jasoliya). Since FXN
deficiency triggers the mitochondrial biogenesis defect in cells, and DMF dose dependently
increases FXN expression (Figs 1 & 5A), the increase in mitochondrial biogenesis we observed
could potentially be the direct consequence of FXN induction.
Discussion
Effect of R-loops on FXN gene expression
GAA repeat expansions in the first intron of the FXN gene result in decreased FXN protein
expression. Understanding the mechanistic relationship between increased GAA repeats and
reduced FXN expression is important to therapeutic approaches for FA. Expanded GAA repeat
generates a region with high G versus C strand asymmetry or GC skew, which thermodynami-
cally favors re-invasion of the GA-rich transcript on the template DNA strand behind the
advancing RNA polymerase, thus forming R-loops. R-loop formation has been shown to play
a vital role in transcription termination in humans and could thus lead to pausing and/ or ter-
mination in the FXN intron1 as observed here (Fig 3).
An alternative, model for the effect of R-loop is the recruitment of repressive histone
marks, leading to the compaction of chromatin [21–23]. Spreading of such repressive modifi-
cations to the promoter region could lead to the epigenetic silencing. Alternatively, chromatin
compaction could lead to reduced elongation through the GAA repeats, as has been observed
[24]. Thus R-loops could decrease FXN expression by causing premature transcription termi-
nation and/or decreasing transcription initiation or elongation because of chromatin
compaction.
Recent evidence also hints at a possible mechanism by which repressive histone marks can
be recruited by R-loops. Formation of R-loops at expanded GAA repeats leaves the GA-rich
non-template DNA strand in a single stranded state that is accessible to the transcription
machinery. This has been shown to trigger antisense RNA transcription [25]. The sense and
antisense FXN transcripts may lead to formation of dsRNA thereby recruiting the RNA inter-
ference machinery and further decreasing the formation of mature FXN transcript by chop-
ping of the existing mRNA using RISC complex and/or formation of repressive histone marks
[23].
DMF induces FXN expression by increased transcriptional initiation
We show that DMF induces FXN expression through increased transcriptional initiation. This
potentially decreases transcriptional pausing (Fig 3) and reduces frequency of R-loop forma-
tion in mutant FXN genes. One possible cause of increased FXN initiation events is increased
activation through the Nrf2 mediated mechanism, as described previously for Dyclonine. In
this view, DMF which is a known Keap1/Nrf2 inducer, triggers Nrf2 binding to 3 Antioxidant
Response Elements (AREs) upstream of the FXN gene, triggering increased transcriptional ini-
tiation [11]. Another possibility is that DMF, that drives the expression of mitochondrial
Dimethyl fumarate dosing in humans increases frataxin expression
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biogenesis factors NRF1 and TFAM [26] drives the expression of all mitochondrial proteins
including FXN as a consequence of increased mitochondrial biogenesis overall (Fig 5).
DMF induces FXN and mitochondrial biogenesis at the concentrations it
reaches in human dosing
Friedreich’s ataxia is a rare, autosomal recessive disease caused by depletion of mitochondrial
protein FXN whose likely role is in Fe-S cluster biogenesis. Loss of FXN results in decrease in
mitochondrial copy number [10], which primarily effects high energy demanding tissues,
including dorsal root ganglia, dentate nuclei cerebellum, skeletal muscle and heart. Primary
clinical features involve progressive loss of muscle coordination and balance, leading to gait
and limb ataxia resulting in being wheel chair bound as the disease progresses. Cardiomyopa-
thy is the leading cause of death in FA [27,28]. Currently there is no approved therapy for FA
[29]. Here we show that DMF, approved for use in humans for multiple sclerosis and psoriasis,
dose-dependently induces both FXN expression whose deficiency is the only cause of FA, and
also induces mitochondrial biogenesis. Both the FXN induction and the mitochondrial bio-
genesis induction are happening at ~10 μM, which is close to the ~7 μM concentration reached
by DMF’s major bioactive metabolite MMF in 480mg dosing in humans.
DMF as a potential therapy for FA
We show that DMF increases FXN expression by 93% in FA derived lymphoblast cell model at
30μM dose, by 52% in FA mice Yg8 at 10mg/kg dose and by 85% in MS patients treated for 3
months. There is a positive co-relation between FA patient FXN level in the blood to age of dis-
ease onset [30]. This modest increase in FXN is highly clinically relevant as increase in FXN by
~80% (Fig 2) has potential to delay the age of FA onset by many years.
Fig 5. DMF increases FXN expression and mitochondrial biogenesis in 48 hr treated patient derived fibroblast cells. Cells were treated with
0.01% DMSO vehicle, 1,3,10 or 30 μM DMF for 48 hr (A) Frataxin mRNA expression measured by qPCR as FXN normalized to Actin. Vehicle,
n = 8; 3μM, n = 1; 10μM, n = 4; 30μM, n = 8; Healthy, n = 3. (B) Mitochondrial DNA copy number was measured by q-PCR analysis as ratio of
mitochondrial DNA over nuclear DNA; mt-TL1/B2M. Vehicle, n = 9; 3μM, n = 3; 10μM, n = 5; 30μM, n = 9; Healthy, n = 3. Bars represent
averages ± standard deviations (p<0.05�, p<0.01��, p<0.001���).
https://doi.org/10.1371/journal.pone.0217776.g005
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It is also important to stress that FXN mRNA expression is reduced to 19.4% in FA patients,
and to 53% in carriers, as compared to healthy controls [31]. Carriers are healthy individuals
that discover their status only during genetic counseling, and their condition has never been
linked to any neurological or cardiological abnormality. Therefore, the increase in FXN
mRNA after DMF treatment may be effective in counteracting the pathological process of
reduced FXN at the increase found after in vivo administration. Thus, DMF is unique, it is safe
and well tolerated, it has more than 200,000 patients treated worldwide for Multiple Sclerosis
and Psoriasis. This suggests that it should be considered as a therapy for Friedreich’s ataxia.
Materials and method
Cell culture & drug treatment
Human lymphoblast cells: Healthy- GM13068; FA-patient derived- GM14518, GM15850,
GM16216, GM16214 and GM16220 were grown in RPMI-1640 supplemented with 15% Fetal
Bovine Serum. Human Fibroblast cells: Healthy- GM3440; FA patient derived- GM04078 were
grown in DMEM supplemented with 12% Fetal Bovine Serum. For both cell types, Media was
changed every two days. These cells were obtained from Coriell Institute for Medical Research
Repository.
For in vitro drug treatment, 2x106 cells were treated with 0.01% DMSO as vehicle control or
1, 3, 10, 30 and 100μM of dimethyl fumarate for 24 or 48 hrs. Post treatment cells are har-
vested, washed with PBS and processed for downstream analysis.
Animal procedure
All animal procedures were approved by the ‘Institutional Animal Care and Use Committee’
at University of California, Davis. 50 mg/ml of DMF was dissolved in DMSO to make stock
solution of DMF. Prior to injection, 0.5 mg/ml of working DMF solution (1:100 dilution) was
made by diluting the stock solution into phosphate-buffered saline with 5% Tween-20 and 5%
polyethylene glycol (Sigma-Aldrich, St. Louis, MO, USA). The mice were injected intraperito-
neally every day for 7 days with 0,3,5and10 mg/kg of DMF. The mice were euthanized with
CO2 followed by cervical dislocation and tissues were immediately removed then flash frozen
with liquid nitrogen. Samples were stored in −80 ˚C until utilized for experiments.
Mice were randomly allocated to 4 dose groups- 0 (vehicle), 3, 5 and 10 mg/kg DMF dose.
Sample size of 4 animals per dose group was determined by power calculation (Mean 1 = vehi-
cle = 1, Mean 2 = 1.2 (20% Frataxin increase), Standard deviation (SD) = 0.1 = 10%, from cal-
culated SDs of many technical replicates of FXN measurements of mouse cerebellum, 2 sided
test, alpha = 0.05 and power of 0.80. Experimenter was no blinded to mice numbers during
intra peritoneal injection, however after the westernblot was performed, images were quanti-
fied objectively by Li-Cor Odyssey software.
Ethics and patients
The local Ethics Committee of the University Federico II of Naples, approved the study. The
study was performed in accordance to the Declaration of Helsinki, European guidelines
CPMP/ICH/135/95, and Italian law D.M.15/07/1997. All patients gave written informed con-
sent before any activity linked to the study was started.
Patients were recruited from the Multiple Sclerosis Center of the Federico II University of
Naples. There were 12 controls, and 27 MS patients. Of these 27 MS patients, 14 were treated
with DMF and 13 with Fingolimod (FTY). Controls demographics were: age, gender. For
DMF treated MS patients: age 42.84±11.9, gender M/F = 8/6, age at onset 29.2±9.8, disease
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duration 13.6±7.1, relapses in the previous year 0.6±0.7, EDSS 4.6±1.9. For FTY treated MS
patients: age 45.9±23.3, gender M/F = 3/10, age at onset 34.2±20.9, disease duration 11.8±6.2,
relapses in the previous year 0.5±0.7, EDSS 3.1±1.2.
Past medical history varied among MS patients. In the DMF cohort, three patients were
treatment naïve for MS specific drugs, five had been previously treated with interferon beta-1a
s.c., two with natalizumab, teo with interferon beta-1b s.c., one with interferon beta-1a i.m.,
one with FTY. In the FTY cohort, three were treatment naïve, three had been previously
treated with interferon beta-1a s.c., two with natalizumab, two with interferon beta-1b s.c.,
three with interferon beta-1a i.m., one with FTY.
Patients were included if a decision to start a therapy with Dimethylfumarate (DMF) or fin-
golimod (FTY) had already been taken as part of clinical practice. We obtained samples on the
day before treatment was started, and after 3 months of continuous DMF or FTY therapy.
Patients treated with DMF received 120 mg, twice a day, for one week and 240 mg twice a day,
for the remaining days until month 3. FTY patients were treated with 0.5 mg FTY for all 3
months. Healthy controls were recruited at our clinic through students and site personnel.
Patients and controls were genotyped for the FXN gene expansions in order to exclude the
presence of expanded alleles.
RNA extraction and qRT-PCR
In in vitro cultured cells, RNA was exrtacted using RNAesay kit (QIAGEN). cDNA was then
synthesized from mRNA with iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA, USA) per manufacturer’s instruction in a C1000 Touch Thermal Cycler (Bio-Rad Labora-
tories, Hercules, CA, USA). A SensiFAST SYBR No-ROX Kit (Bioline, Taunton, MA, USA)
was used to perform qPCR on the synthesized cDNA in a Roche Lightcycler 480 (Roche Diag-
nostics, Indianapolis, IN, USA). The second derivative of the amplification curve was used to
determine the cycle threshold, and the data were analyzed by a delta delta CT calculation.
Primer sets used in qPCR are listed in S2 Table.
For FXN gene expression in DMF treated patients, PBMCs were extracted from 30 mL of
EDTA anticoagulated whole blood using Leucosep tubes (Greiner bio-one, Frickenhausen,
Germany) and frozen at -80˚C until analysis. Total mRNA was extracted from PBMCs using
RIboPure RNA Purification Kit (ThermoFisher Scientific, Waltham, MA, USA) following
manufacturer’s instructions. 500 ng mRNA was reversely transcribed using the one-step High
Capacity RNA-to-cDNA Master Mix (ThermoFisher Scientific, Waltham, MA, USA) follow-
ing manufacturer’s instructions in a total volume of 20μL. mRNA was quantified using a Gene
Expression Assay for frataxin (Life Sciences, catalog n. Hs00175940_m1) and standardized by
quantification of hypoxanthine phosphoribosyl-transferase 1 as a reference gene. Relative
expression was calculated with the efficiency-calibrated model as previously described [32]
Western blot
Cells/ mice tissues were lysed using lysis buffer (Cell Signalling) supplemented with a complete
protease inhibitor cocktail (Roche Applied Science) and phenylmethylsulfonyl fluoride
(Sigma-Aldrich Corp.). Tissues were further homogenized using 0.5 mm glass beads in a Bullet
Blender high-throughput homogenizer (Next Advance, Inc.). After pelleting cellular debris by
spinning at 16000 rpm at 4˚C for 15 min, protein was quantified by Bradford assay. Detailed
procedure for western blotting has been described previously [26]. In brief, 40–50 μg protein
was added per lane of 4–12% Bis-Tris gels (Invitrogen Corp.). Primary antibodies were diluted
in Odyssey blocking buffer (LI-COR Biosciences). Antibodies used included: anti-FXN (pro-
vided by Franco Taroni M.D., Istituto Besta) and anti-actin (#A2668, Sigma). Direct
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conjugated secondary antibodies (anti-rabbit IRdye800Cw and anti-mouse IRdye680 from
LI-COR) were used to detect and quantify the signal of primary antibodies and imaged using a
LI-COR Odyssey.
Harvesting nucleic acids for DRIP
Cell pellets were washed with DPBS (Life Technologies) and resuspended in 4 mL of 10 mM
Tris-HCl, 10 mM EDTA, 100 mM NaCl pH 8, lysed with 0.5% SDS, and digested with 400
units of Proteinase K (Thermo Fisher Scientific, Waltham, MA) at 37˚C overnight. Cell lysates
were then extracted once with 1 volume of equilibrated phenol pH 8 (USB, Cleveland, OH)
and twice with 1 volume of chloroform (Sigma-Aldrich). DNA was precipitated with 1 volume
of isopropanol and 300 mM sodium acetate, and was swirled out of solution with a glass shep-
herd’s hook. The DNA pellet was washed twice by rinsing the hook with 400 μL of 70% etha-
nol, and was rehydrated in 10 mM Tris-HCl pH 8.
DRIP-PCR
Harvested nucleic acids (*50 μg) were digested using a restriction enzyme cocktail (20 units
each of EcoRI, HindIII, BsrGI, PuvI, Ssp1) (New England Biolabs, Ipswich, MA; NEB) over-
night at 37˚C in 1× NEBuffer 2. Digests were cleaned by phenol and chloroform extraction fol-
lowed by precipitation in isopropanol. The resulting fragmented DNA was pelleted at full
speed (16,100× g) at 4˚C and washed twice with 70% ethanol. Air-dried pellets were rehy-
drated in 10 mM Tris-HCl pH 7.5, 1 mM EDTA (TE).
We adapted the previously described DRIP protocol [13]. Six to eight μg of digested nucleic
acids were diluted in 450 μL of TE, and 10 μL was reserved as input for qPCR. Fifty-two μL of
10× IP buffer was added for a final buffer concentration of 10 mM sodium phosphate, 140
mM sodium chloride, 0.05% Triton X-100, and 20 μL of S9.6 antibody (1 mg/ml; KeraFAST)
The samples were incubated with the antibody at 4˚C for 2 hours. This incubation and all
wash steps were performed on a rotisserie mixer. 40 μL of Protein A/G Agarose beads (Pierce,
Rockford, IL) was washed twice with 800 μL of 1× IP buffer for 5 minutes at room tempera-
ture. After adding agarose beads to each sample, they were incubated for 2 hours at 4˚C. Each
DRIP was then washed three times with 700 μL 1× IP buffer for 10 minutes per wash at room
temperature. After the final wash, the agarose beads were resuspended in 250 μL of 1× IP
buffer and incubated with 60 units of Proteinase K for 30 minutes at 50˚C. Digested DRIP
samples were then cleaned with phenol/chloroform extraction and isopropanol precipitation.
Air-dried DRIP pellets were resuspended in 80 μL of 10 mM Tris-HCl pH 8.
We used 10 μL reactions with Sensi-FAST Lo-Rox 2× qPCR mix (Bioline, London, UK) to
assay for genomic loci on FXN gene using Primer listed in the S2 Table. For each DRIP sample,
5 μL of the output and 5 μL of diluted input (1∶100) were assayed in triplicate. Fold enrichment
for a given locus was calculated using the comparative Ct method.
Materials
Dimethyl Fumarate was purchased from (Sigma-Aldrich, St. Louis, MO, USA) and stock solu-
tion was prepared in DMSO. Media for cell culture was obtained from (Corning, Inc., NY,
USA) and Fetal Bovine Serum from Fetal Bovine Serum (JR Scientific, Woodland, CA).
Statistics
Cell and Mice data are expressed as mean ± standard deviation. Relative comparison of data
was performed with a t-test or one-way repeated measures analysis of Variance (ANOVA)
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using a host hoc Bonferroni correction. All statistical analysis was performed with Prism
(GraphPad Software, La Jolla, USA) Differences were considered significant when p<0.05.
For Human dosing data, normality was tested with the Kolmogorov-Smirnov test. P values
less than 0.05 were considered significant. The effect of DMF and FTY on frataxin expression
was analyzed with a General Linear Model for repeated measures with FXN expression as the
dependent variable at baseline and 3 months after treatment, and drug as a factor. Statistical
analysis was performed with SPSS 23.0.0.2 running on MacOS 10.11.6.
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